Relmada Therapeutics SG&A Expenses 2013-2024 | RLMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Relmada Therapeutics sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Relmada Therapeutics sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.7B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$19.3B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.4B
Summit Therapeutics (SMMT)	$13.6B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$11.8B
Catalent (CTLT)	$10.8B
Jazz Pharmaceuticals (JAZZ)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7.2B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.3B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2.4B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Centessa Pharmaceuticals (CNTA)	$2.1B
Evotec AG (EVO)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.7B
Recursion Pharmaceuticals (RXRX)	$1.6B
Harrow (HROW)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Cassava Sciences (SAVA)	$1.5B